A 60-year-old male presented with a history of anorexia, nausea, vomiting, epigastric pain, and generalized weakness for 2 weeks. He was a known case of nephrotic syndrome, diagnosed 3 months back. Since then he was on prednisolone, started at 50 mg daily and then tapered to 20 mg/day. On presentation, he was hemodynamically stable, but malnourished with a body mass index of 17.5 kg/m². On evaluation, he was found to have dyselectrolytemia (serum sodium: 121 mEq/L, magnesium: 1.5 mg/dL), severe hypoalbuminemia (serum albumin: 1.7 g/dL), and raised C-reactive protein (93 mg/dL). Upper gastrointestinal (GI) endoscopy revealed diffuse ulcerations in the entire stomach and duodenum (► Fig. 1). A biopsy was taken from stomach for histopathological examination. The biopsy showed increased inflammatory cells along with infiltration of the larval forms of *Strongyloides stercoralis* into the lumen of gastric mucosal glands (► Fig. 2). The patient was treated with oral
ivermectin for 2 weeks. On follow-up, the patient had resolution of his GI symptoms as well as healing of gastroduodenal ulcers.

The spectrum of *Strongyloides* infection can range from asymptomatic subclinical disease to life-threatening hyperinfection syndrome and disseminated disease. In hyperinfection syndrome, the GI tract and the lungs are usually involved. Disseminated strongyloidiasis usually occurs in immunocompromised hosts, and can involve multiple organs. Both hyperinfection and disseminated disease have a high mortality in untreated cases (up to 90%). Endoscopic findings include erythema, nodules, exudates, erosion, and ulcers. Although endoscopic findings are not diagnostic, histopathological demonstration of larval forms in biopsy specimen can clinch the diagnosis. Our patient was an immunocompromised patient on immunosuppressant. He developed a hyperinfection syndrome that could be managed with timely diagnosis and treatment.

**Ethical Statement**  
Not applicable.

**Authors’ Contributions**  
All authors contributed equally to the article.

**Data Availability Statement**  
None.

**Funding**  
None.

**Conflict of Interest**  
None declared.

**Acknowledgments**  
None.

**References**